Analyst Price Target is $7.00
▲ +695.45% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Chemomab Therapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 695.45% upside from the last price of $0.88.
Current Consensus is
Hold
The current consensus among 1 polled investment analysts is to hold stock in Chemomab Therapeutics. This Hold consensus rating has held steady for over two years.